Unlocking the Mdm2-p53 loop: Ubiquitin is the key

Mdm2 has been thought to regulate the tumor suppressor p53 in two ways: by masking p53’s access to transcriptional machinery, and by ubiquitinating p53, targeting it for proteasomal degradation. This dogma was recently challenged by data generated from knockin mice in which Mdm2’s RING E3 ubiquitin ligase activity was abrogated by a single point mutation. The RING mutant Mdm2 is fully capable of binding with p53, yet cannot suppress p53 activity, suggesting that Mdm2 cannot block p53 by binding alone, without ubiquitination. Data from the RING knockin mice also revealed that endogenous Mdm2 does not, as previously thought, regulate its own stability by self-ubiquitination. In this review, we will discuss these findings and their relevance to the field, including potential reasons for the discrepancies between previous data and that generated by our knockin mice, as well as the feasibility of targeting Mdm2’s E3 ubiquitin ligase activity in cancer. We will also discuss additional research questions that may be addressed using our mouse model.

[1]  R. Copeland,et al.  Quantitative assays of Mdm2 ubiquitin ligase activity and other ubiquitin-utilizing enzymes for inhibitor discovery. , 2005, Methods in enzymology.

[2]  Lawrence A. Donehower,et al.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 , 1995, Nature.

[3]  M. Jackson,et al.  MdmX Protects p53 from Mdm2-Mediated Degradation , 2000, Molecular and Cellular Biology.

[4]  Ken Chen,et al.  The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.

[5]  Jun Qin,et al.  ARF-BP1/Mule Is a Critical Mediator of the ARF Tumor Suppressor , 2005, Cell.

[6]  G. Wahl,et al.  A New Twist in the Feedback Loop: Stress-Activated MDM2 Destabilization is Required for p53 Activation , 2005, Cell cycle.

[7]  Yue Xiong,et al.  ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.

[8]  G. Evan,et al.  Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. , 2007, Cancer cell.

[9]  R. Honda,et al.  Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase , 2000, Oncogene.

[10]  A. Levine,et al.  The MDM2 Oncoprotein Binds Specifically to RNA through its RING Finger Domain , 1996, Molecular medicine.

[11]  S. Letteboer,et al.  Hdmx Protein Stability Is Regulated by the Ubiquitin Ligase Activity of Mdm2* , 2003, Journal of Biological Chemistry.

[12]  Bert Vogelstein,et al.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.

[13]  M. Kubbutat,et al.  Regulation of HDM2 activity by the ribosomal protein L11. , 2003, Cancer cell.

[14]  S. Francoz,et al.  Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[15]  C. Maki,et al.  The MDM2 RING-finger domain is required to promote p53 nuclear export , 2000, Nature Cell Biology.

[16]  C. Prives,et al.  Unleashing the power of p53: lessons from mice and men. , 2006, Genes & development.

[17]  R. Tjian,et al.  Repression of p53-mediated transcription by MDM2: a dual mechanism. , 1997, Genes & development.

[18]  O. Cuvier,et al.  Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2 , 2007, Nature Cell Biology.

[19]  A. Jochemsen,et al.  Mdmx and Mdm2: Brothers in Arms? , 2004, Cell cycle.

[20]  A. Ciechanover,et al.  HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  K. Shirouzu,et al.  MDM2 interacts with MDMX through their RING finger domains , 1999, FEBS letters.

[22]  G. Wahl,et al.  Accelerated MDM2 auto‐degradation induced by DNA‐damage kinases is required for p53 activation , 2004, The EMBO journal.

[23]  G. Peters,et al.  Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus , 2001, Nature Cell Biology.

[24]  D. George,et al.  Stabilization of the MDM2 Oncoprotein by Interaction with the Structurally Related MDMX Protein* , 1999, The Journal of Biological Chemistry.

[25]  G. Wahl,et al.  A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. , 2006, Cancer cell.

[26]  M. Rolfe,et al.  Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[28]  Hirofumi Tanaka,et al.  Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 , 1997, FEBS letters.

[29]  N. Little,et al.  Hdmx stabilizes Mdm2 and p53. , 2000, The Journal of biological chemistry.

[30]  Mihee M. Kim,et al.  RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity. , 2007, Cancer research.

[31]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[32]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[33]  G. Wahl,et al.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.

[34]  A. Levine,et al.  Regulation of Transcription Functions of the p53 Tumor Suppressor by the mdm-2 Oncogene , 1995, Molecular medicine.

[35]  Yu Pan,et al.  MDM2 Promotes Ubiquitination and Degradation of MDMX , 2003, Molecular and Cellular Biology.

[36]  M. Oren,et al.  The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression. , 2004, Molecular cell.

[37]  G. Evan,et al.  Temporal dissection of p53 function in vitro and in vivo , 2005, Nature Genetics.

[38]  Guillermina Lozano,et al.  Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.

[39]  M. Kubbutat,et al.  Identification of a cryptic nucleolar-localization signal in MDM2 , 2000, Nature Cell Biology.

[40]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[41]  Charles J. Sherr,et al.  Nucleolar Arf sequesters Mdm2 and activates p53 , 1999, Nature Cell Biology.

[42]  Guillermina Lozano,et al.  Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation , 2003, Cell.

[43]  L. Vassilev,et al.  MDM2 inhibitors for cancer therapy. , 2007, Trends in molecular medicine.

[44]  T. Allio,et al.  Ribosomal Protein L11 Negatively Regulates Oncoprotein MDM2 and Mediates a p53-Dependent Ribosomal-Stress Checkpoint Pathway , 2003, Molecular and Cellular Biology.

[45]  Andrea Ciliberto,et al.  Steady States and Oscillations in the p53/Mdm2 Network , 2005, Cell cycle.

[46]  Jeremy R Stuart,et al.  DNA Damage-induced MDMX Degradation Is Mediated by MDM2* , 2003, Journal of Biological Chemistry.

[47]  Patrick Dowd,et al.  The ubiquitin ligase COP1 is a critical negative regulator of p53 , 2004, Nature.

[48]  Pankaj Oberoi,et al.  Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. , 2005, Cancer cell.

[49]  Shengyun Fang,et al.  Mdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53* , 2000, The Journal of Biological Chemistry.

[50]  M. Chalfie,et al.  Nucleotide binding by the Mdm2 RING domain facilitates Arf-independent Mdm2 nucleolar localization. , 2003, Molecular cell.